Product name

Summary

Organization name

Profile

Although analysis of gene expression patterns using nucleic acid microarrays has become a powerful tool in genomic- and proteomic-scale studies, the results of these screens do not detect the presence of the expressed gene product, namely the protein. Only monoclonal antibodies and related affinity reagents detect the functional unit itself, and are therefore powerful and desirable tools in this detection process.

Mouse derived monoclonal antibodies continue to be the affinity reagent of choice in proteomics analyses, but their production against novel targets remains restricted by high tissue culture load and low-throughput screening methods. Other techniques more amenable to high-throughput production of high affinity detection reagents are still unable to yield high affinity antibodies without lengthy downstream manipulation.

We circumvented two obstacles to increase the mAB production throughput level. The first is the number of tissue culture operations necessary for performing multiple fusions simultaneously using only one antigen per animal. The second is screening the many thousands of culture supernatants generated by large-scale production. Recent advances in proteomics research underscore the increasing need for highaffinity monoclonal antibodies, which are still generated with lengthy, lowthroughput antibody production techniques.

Technology

Here we present a semi-automated, high-throughput method of hybridoma generation and identification. Monoclonal antibodies were raised to different targets in single batch runs of 6-10 weeks using multiplexed immunisations, automated fusion and cell-culture, and a novel antigen-coated microarray-screening assay. With this technology we generated in a large-scale run, where eight mice were immunized with ten antigens each, monoclonal antibodies against 68 of the targets (85%), within 6 weeks of the primary immunization.

Commercial Opportunity

Our technology enables you to increase your quality and quantity of monoclonal antibodies and will significantly reduce your production cost.

We offer:

• Licensing and full technology transfer of the technology platform
• Technology evaluation program
• Collaboration

Developmental Status

The proven and robust technology is implemented and has been evaluated within EMBL and at several external sites. It is in daily use in EMBL´s Monoclonal Antibody Core Facility.

European and Singapore applications have been filed.

Contact

EMBLEM
Dr. Martin Raditsch
Raditsch(at)embl-em.de

About EMBLEM

EMBL Enterprise Management Technology Transfer GmbH (EMBLEM) is an affiliate and the commercial arm of the European Molecular Biology Laboratory (EMBL). EMBLEM, established in 1999 identifies, protects and commercialises the intellectual property developed in the EMBL-world, from EMBL-alumni and from third parties. EMBLEM facilitates and accelerates the transfer of innovative technology from basic research to industry by working closely with industrial partners spanning the biotech, ITC and mechanical/electrical engineering markets to develop new diagnostics, drugs, therapies and machines and devices.

Description File

URL

Your feedback

back